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Introduction 
Sepsis is still a major cause of morbidity and mortality in neonates, especially in preterm 
infants.  Mortality can reach 60-70% in very low birth weight infants (birthweight <1500 
g).  Since this condition can rapidly progress to severe sepsis, septic shock and multiple 
organ dysfunction syndrome, early diagnosis is crucial to improve survival.  Unfortunately, 
diagnosis may be difficult in the neonate: the earliest signs of the disease are often subtle 
and aspecific.  Blood culture is the gold standard for the diagnosis of sepsis, but at least 48-
72 hours are needed for the results and the number of false negative is not negligible.  In 
2005, Endo & al. identified a new biomarker, named presepsin (soluble CD14 subtype), 
that has proven to be a promising diagnostic and prognostic marker of sepsis in adult [1]. 
Objective 
Data on presepsin in large cohorts of neonates have never been reported, neither for healthy 
nor for septic babies.  Thus we planned a study to determine the reference range for 
presepsin in healthy term and preterm neonates. 
Methods 
This was a cohort study, carried out at the Neonatal Unit of Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico of Milan, Italy, between February 2014 and August 2014.  
Healthy 484 term (37 to 42 weeks’ gestation) and 200 preterm (<37 weeks) neonates 
without clinical infection, according to CDC criteria [2], were enrolled in the study.  
Presepsin levels were determined on 100-200 μL of whole blood obtained via heel puncture 
or venipuncture from term neonates on day 3 of life, and from preterm neonates between 49 
and 120 hours of life.  Presepsin concentrations were measured using a compact fully 
automated immunoassay analyzer, PATHFAST
®
 System (Mitsubishi Chemical Medience 
Corporation; Gepa Diagnostic, Milan, Italy). 
Results  
Term neonates.  Among all the factors possibly affecting presepsin levels, the univariable 
analysis showed that those associated to the largest differences were Apgar at 1 min (≥8: 
645 pg/ml  11.9 vs <8: 767 pg/ml  55.9), and multiple birth (twins: 538 pg/ml  62.2 vs 
singletons: 653 pg/ml  11.9).  Anyhow, when simultaneously introduced into a 
multivariable linear model, all factors accounted only for 5.0% of the total sum of squares.  
A more parsimonious multivariable linear model was fitted after removing the factors that 
showed the lowest effect on presepsin level (those associated with a p-value >0.20).  This 
reduced model explains 3.8% of the total sum of squares.  After adjustment for all the 
factors in the model, presepsin levels appear to be significantly lower in twins (496 pg/ml  
65.5 vs 655 pg/ml  11.8) and in neonates with Apgar at 1 min ≥8 (644 pg/ml  11.8 vs 774 
pg/ml  56.2).  So none of the above factors seems worth to be taken into account in 
determining the reference limits for presepsin blood levels in healthy term neonates. 
Preterm neonates.  The largest differences in presepsin level are observed between small for 
gestational age (SGA) (903 pg/ml  57.1) and adequate for gestational age (AGA) neonates 
(703 pg/ml  26.7), between neonates with and without mechanical ventilation at blood 
sampling (1090 pg/ml  86.9 vs 711 pg/ml  24.7) and at delivery (855 pg/ml  87.3 vs 729 
pg/ml  25.8), between neonates with and without venous catether (801 pg/ml  47.5 vs 
716 pg/ml  28.9), between neonates who underwent blood sampling after the 4th day or 
before (797 pg/ml  46.2 vs 716 pg/ml  29.2), between males and females (778 pg/ml  
35.1 vs 701 pg/ml  34.7).  All these factors, when simultaneously introduced into a 
multivariable linear model, explain only 18.8% of the total sum of squares.  A second 
multivariable linear model was fitted after removing the factors that showed the lowest 
effect on presepsin level (those associated with a p-value >0.50).  This reduced model 
explains 13.4% of the total sum of squares.  A third and more parsimonious multivariable 
linear model was fitted after removing the factors that showed the lowest effect on 
presepsin level (those associated with a p-value >0.20).  This reduced model explains 
12.3% of the total sum of squares.  After adjustment for all the factors in the model, 
presepsin levels result to be significantly lower in AGA neonates (706 pg/ml  25.7 vs 890 
pg/ml  55.0) and between neonates with and without mechanical ventilation at blood 
sampling (1074 pg/ml  85.3 vs 712 pg/ml  24.2).  Even in this case, none of the above 
factors is expected to substantially affect the reference limits for presepsin blood levels in 
preterm neonates. 
Conclusion  
Presepsin blood levels seem to be quite independent of most of maternal and neonatal 
conditions examined in this study both in preterm and term neonates.  The factors exerting 
significant effects (multiple birth and Apgar at 1 min, in term neonates, weight by 
gestational age and mechanical ventilation in preterm neonates) are expected to affect 
presepsin reference limits only to minor extent. 
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